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Combatting Antibacterial Resistance With Phage Therapy 
Linda Line
Southern Maine Community College, South Portland Maine
ABSTRACT
Phage therapy is the use of viruses to treat bacterial infections. This
therapeutic method offers a viable solution to antibiotic resistance
among pathogenic bacteria. In this review, we discuss the strengths
and weaknesses of phage therapy. Phages attack specific hosts,
making them more narrow-spectrum than antibiotics. Adding genes
for infection-fighting peptides to the genome may improve the
effectiveness of phage therapy. Antimicrobial regulator peptide
IDR-1018 is involved in modulation of the immune system. A
research group has shown that incorporating a gene for IDR-1018
into phage T7 significantly increased the bactericidal effects
in Escherichia coli. In another study, phage lysin PlyF307, a
peptide that lyses bacterial cells, resulted in an increased ability to
eliminate biofilm when added to a genome of Acinetobacter
baumannii strain 1791. Researchers observed promising results in
a mice study with this modified phage. Studies done both in vivo
and in vitro have shown that phage can be modified to enhance
their ability for use in phage therapy. Further research has
addressed the weaknesses of phage therapy. While specificity is a
limitation, so is bacterial resistance rate. Bacteria, highly equipped
organisms, have shown resistance to particular phages. Through
modification of the phage genome, we can decrease the frequency
of bacterial resistance while increasing bactericidal activity. These
studies suggest there may be ways to modify phages to overcome
the limitations of host range and host resistance.
INTRODUCTION
Ø Discovered in the early 1900s, phage therapy is the use of
bacterial viruses, known as bacteriophages, to inhibit and destroy
infectious, pathogenic, bacterial cells.
ØMulti-drug-resistant bacteria have become a widespread global
health concern, and the incorporation of phage therapy into the
medical field offers a viable solution.
Ø Phages are highly specific organisms, meaning they will only
infect the bacterial cells they were designed to and not the hosts'
cells, eliminating the worry of harm to the human body.
Ø Specificity can be a limitation resulting in decreased potential of
multispecies effectiveness; however, with advanced technology,
scientists can overcome this issue via genome modification.
ØModification is the structural alteration of an organisms’ genomic
DNA/RNA through the introduction of chemicals, such as peptides
or lysins.
Ø Lysins and immunomodulatory peptides not only increase the
efficiency rate of phage but also boosts the hosts' immune system,
broadens the host range, and enhances antibacterial activity.
Ø This review highlights the advancements in phage therapy, the
importance of modification, and discusses what these successful
studies mean for our future.
Fig. 3. Analyzing the effects of PlyF307 in Acinetobacter baumannii
biofilms. This figure identifies the effectiveness of in vivo modification.
Mice were infected with 108 CFU (Colony-Forming Units) of A. baumannii
and two hours later injected with the enhanced strain 1791 modified lysin
PlyF307 (a single domain lysozyme known to inhibit gram-negative
bacteria), under the skin, for a duration of 24 hours, two doses of 1mg
PlyF307 at four-hour intervals. With these results, 90% of the untreated
mice died within 48hrs, while the mice treated with the lysin modified
phage had a significantly higher survival rate, observing an increase of
50%. (Lood, et al., 2015)
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How can modification of phage be beneficial?
How is phage therapy useful to humans?
CONCLUSION
This review expands upon how the genomic modification of phage may be a
solution to antibiotic resistance. There has been an increase of antibacterial
resistant species; with how progressive bacteria are, the need to address this
issue is becoming more prevalent. Phage are abundant, highly specific,
microscopic organisms that scientists can manipulate and engineer rapidly
to expand the host range and generate variants to combat infectious
diseases. With known success rates greater than 50% in vivo, phage
research has great potential that is yet to be exploited.
q Helping with autoimmune diseases. With only 1% chance of 
survival, a 16-year-old cystic fibrosis patient suffered from a deadly 
infection of antibacterial resistant Mycobacterium abscessus after a  
double lung transplant. The infection spread from the lungs to the 
liver and caused skin lesions. This image (Fig. 2) shows the 
infection within the patients' liver. The “Post-treatment” image is 
three weeks later, after receiving phage infusions twice a day, the 
infection is 90% inhibited.  Scientists engineered a phage cocktail to 
treat the bacterial infection. This is the result of splicing multiple 
phage genomes together in order to produce one highly destructive 
organism. (Dedrick et al., 2019)
q Phage therapy has shown promising results in helping to deplete 
cancerous brain cells. In this specific study, researchers used 
modified phage M13 (of the enterobacteria family) to increase 
effectiveness of the alkylating agent temozolomide (TMZ). This was 
done by enhancing the phage genome with the TMZ agent and target 
receptors from glioblastoma cell walls allowing the phage to bind to 
the tumor. In vivo studies on mice have led to size reduction of 
tumors and also resulted in complete inhibition of  cancerous cells 
within one month. Human trials are hoped to begin in the next few 
years in the UK and Europe. (Przystal et al., 2019)
q Phage therapy has been studied for decades in countries such as Russia, France, and Egypt. One
advancement is the use of phage to quickly heal topical burns and prevent infection. Scientists have used
bandages, soaked in phage-enhanced liquids, in order to treat the infections of multi-drug resistant
bacteria. Researchers in Egypt found clinical success when studying the antibacterial resistant Klebsiella
pneumonia. A group of 49 infected burn victims were dressed in phage enhanced bandages for 17 days.
42 of the 49 patients resulted in complete recovery while the other 7 had partial recovery. Another study
in France resulted in a 50% success rate of treating burn victims with Pseudomonas aeruginosa
infections within 14 days.
Fig. 4. Observations of unmodified T7select phage and modified 1018 T7
phage effectiveness on four-day old Escherichia coli BL21 biofilm. Here
we analyze that the 1018 phage is more effective than T7select. Bactericidal
activity was recorded within 30 minutes of initial contact whereas the
unmodified T7select phage did not inhibit growth until 60 minutes. While
both phages resulted in 90% bactericidal effects, the modified phage was
able to destroy the infectious cells at a much quicker rate than an
unmodified phage. (Lemon, et al., 2019)
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